u/Both_Leopard_1132

Novo Nordisk is a leader in the GLP-1 market, a structural duopoly, and is aggressively returning capital to shareholders via dividends and large-scale share buybacks. The market is overreacting to short-term "noise" and competitor news, creating a temporary price dip. This allows investors to buy shares at a discount while the company itself is also buying back its own stock, creating a price floor. The current sell-off is an irrational buying opportunity, as the company's long-term fundamentals, market position, and shareholder-friendly capital allocation are being ignored. New, more effective competitor drugs emerge faster than expected, manufacturing expansion faces delays, pricing pressure from governments or insurers intensifies, or unforeseen negative side effects of GLP-1s are discovered.